184 related articles for article (PubMed ID: 26990598)
1. An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence.
Rafia R; Dodd PJ; Brennan A; Meier PS; Hope VD; Ncube F; Byford S; Tie H; Metrebian N; Hellier J; Weaver T; Strang J
Addiction; 2016 Sep; 111(9):1616-27. PubMed ID: 26990598
[TBL] [Abstract][Full Text] [Related]
2. Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial.
Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L;
J Clin Virol; 2016 Jan; 74():66-72. PubMed ID: 26679830
[TBL] [Abstract][Full Text] [Related]
3. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial.
Weaver T; Metrebian N; Hellier J; Pilling S; Charles V; Little N; Poovendran D; Mitcheson L; Ryan F; Bowden-Jones O; Dunn J; Glasper A; Finch E; Strang J
Lancet; 2014 Jul; 384(9938):153-63. PubMed ID: 24725468
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.
Topp L; Day CA; Wand H; Deacon RM; van Beek I; Haber PS; Shanahan M; Rodgers C; Maher L;
Prev Med; 2013 Oct; 57(4):297-303. PubMed ID: 23639625
[TBL] [Abstract][Full Text] [Related]
6. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
7. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of universal newborn hepatitis B vaccination in China.
Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
11. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
13. Disease burden of chronic hepatitis B among immigrants in Canada.
Wong WW; Woo G; Heathcote EJ; Krahn M
Can J Gastroenterol; 2013 Mar; 27(3):137-47. PubMed ID: 23516678
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
15. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
17. An economic evaluation of universal vaccination against hepatitis B virus.
Fenn P; Gray A; McGuire A
J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
[TBL] [Abstract][Full Text] [Related]
18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.
Levaux HP; Schonfeld WH; Pellissier JM; Cassidy WM; Sheriff SK; Fitzsimon C
Pediatrics; 2001 Aug; 108(2):317-25. PubMed ID: 11483794
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
